Study combining chest radiation and immunotherapy for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding radiation to the chest area can improve the effectiveness of maintenance immunotherapy (atezolizumab) in patients with extensive-stage small cell lung cancer who have responded well to initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer.
- You are 18 years or older.
- You have a performance status (ECOG) of 0, 1, or 2, meaning you are able to carry out daily activities with some help if needed.
- Your cancer showed at least a partial response to initial chemo-immunotherapy (Impower 133 regimen).
- You have not had radiation to the chest area before.
- Your lung function tests show FEV1 ≥ 1.2 liters or >40% predicted, and DLCO ≥ 50% predicted.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether giving additional targeted radiation to the chest can help people with extensive-stage small cell lung cancer after they finish standard chemo-immunotherapy. It may help control the cancer in the lung area and prevent it from coming back there.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
This study tests using a shorter course of radiation (hypofractionated radiotherapy) combined with immunotherapy for people with limited-stage small-cell lung cancer. The goal is to see if this approach works better at controlling the cancer and may cause fewer side effects.
This trial tests whether adding radiation therapy to the chest during maintenance immunotherapy can help people with extensive-stage small cell lung cancer live longer. You may be eligible if you've already had chemotherapy plus immunotherapy and your cancer has shrunk or stayed stable.
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
This trial tests a low dose of radiation to the chest followed by a combination of an immunotherapy drug (adebrelimab) and chemotherapy for extensive-stage small cell lung cancer. Afterward, you would continue taking adebrelimab alone as maintenance therapy.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.